1. Home
  2. FRGT vs ENTO Comparison

FRGT vs ENTO Comparison

Compare FRGT & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FRGT
  • ENTO
  • Stock Information
  • Founded
  • FRGT 2015
  • ENTO 2014
  • Country
  • FRGT Mexico
  • ENTO United States
  • Employees
  • FRGT N/A
  • ENTO N/A
  • Industry
  • FRGT Professional Services
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • FRGT Consumer Discretionary
  • ENTO Health Care
  • Exchange
  • FRGT Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • FRGT 2.3M
  • ENTO 1.9M
  • IPO Year
  • FRGT N/A
  • ENTO 2016
  • Fundamental
  • Price
  • FRGT $2.48
  • ENTO $0.52
  • Analyst Decision
  • FRGT
  • ENTO
  • Analyst Count
  • FRGT 0
  • ENTO 0
  • Target Price
  • FRGT N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • FRGT 1.0M
  • ENTO 3.2M
  • Earning Date
  • FRGT 05-16-2025
  • ENTO 06-17-2025
  • Dividend Yield
  • FRGT N/A
  • ENTO N/A
  • EPS Growth
  • FRGT N/A
  • ENTO N/A
  • EPS
  • FRGT N/A
  • ENTO N/A
  • Revenue
  • FRGT $13,541,802.00
  • ENTO N/A
  • Revenue This Year
  • FRGT $371.03
  • ENTO N/A
  • Revenue Next Year
  • FRGT N/A
  • ENTO N/A
  • P/E Ratio
  • FRGT N/A
  • ENTO N/A
  • Revenue Growth
  • FRGT N/A
  • ENTO N/A
  • 52 Week Low
  • FRGT $2.05
  • ENTO $0.19
  • 52 Week High
  • FRGT $170.00
  • ENTO $2.64
  • Technical
  • Relative Strength Index (RSI)
  • FRGT 39.44
  • ENTO 69.29
  • Support Level
  • FRGT $2.05
  • ENTO $0.35
  • Resistance Level
  • FRGT $2.79
  • ENTO $0.50
  • Average True Range (ATR)
  • FRGT 0.37
  • ENTO 0.08
  • MACD
  • FRGT -0.05
  • ENTO 0.01
  • Stochastic Oscillator
  • FRGT 20.38
  • ENTO 51.85

About FRGT Freight Technologies Inc.

Freight Technologies Inc is a technology company developing solutions to optimize and automate the supply chain process. Along with its subsidiary, Freight App, Inc, the group is focused on making shipping transparent and efficient. Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility, and simplicity for the once-complex process of international over-the-road (OTR) shipping. The company uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: